Andrew Cheng - Mar 1, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President & CEO, Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Mar 1, 2022
Transactions value $
-$169,750
Form type
4
Date filed
3/2/2022, 07:40 PM
Previous filing
Feb 3, 2022
Next filing
May 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $6.15K +10K +3.24% $0.62* 319K Mar 1, 2022 Direct
transaction AKRO Common Stock Sale -$176K -10K -3.13% $17.59 309K Mar 1, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -10K -3.22% $0.00 301K Mar 1, 2022 Common Stock 10K $0.62 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $17.33 to $17.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 25% of this option vested on October 1, 2019, and the remaining 75% of this option shall vest and become exercisable in 36 equal monthly installments thereafter.